The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Comparative pharmacokinetic studies of three asparaginase preparations.
Abstract
PURPOSE: As part of pharmacologic studies of asparaginase (ASNase), we determined the half-life of ASNase activity and protein, and the effect of dose, repeated doses, different drug preparations, and hypersensitivity reactions on the half-life (t1/2) of serum ASNase activity. PATIENTS AND METHODS: We measured ASNase activity (spectrophotometric assay) in serum samples obtained from patients with acute lymphoblastic leukemia (ALL) at various times during their therapy with intramuscular ASNase. ASNase protein was measured by enzyme-linked immunoadsorbent assay (ELISA). RESULTS: Studies following the initial dose of Escherichia coli-derived ASNase demonstrated no difference in apparent t1/2 following 25,000 IU/m2 versus 2,500 IU/m2 (1.24 v 1.35 days, P = .2). The apparent t1/2s following maintenance doses of E coli ASNase (middle dose t1/2, 1.28 days, or last dose t1/2, 1.14 days) showed no difference when compared with the initial dose of ASNase (P = .3 to .9). There was no significant difference between the apparent t1/2s of ASNase activity and ASNase protein (n = 8, P = .2 to .6). The serum t1/2 was 0.65 and 5.73 days for patients receiving Erwinia or polyethylene glycol (PEG)-modified E coli ASNase, respectively, as the induction dose. ASNase activity was undetectable in sera of four patients studied in the week following an anaphylactic reaction to E coli ASNase and the t1/2 was significantly shorter in five patients with a history of allergic reaction to E coli ASNase who were studied following a dose of PEG ASNase, (t1/2, 1.80 days). CONCLUSION: We conclude that (1) the apparent t1/2 of ASNase is dependent on enzyme preparation used, but is not affected by dose or by repeated use; (2) the apparent t1/2 of E coli ASNase as a protein is the same as the apparent t1/2 of enzymatic activity; and (3) patients who have had a hypersensitivity reaction to E coli ASNase have a decreased apparent t1/2 with both E coli and PEG ASNase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BROOME, J. D. (1961) · Nature · doi:10.1038/1911114a0 · Cited by 459
Clavell, L. A., Gelber, R. D., Cohen, H. J., Hitchcock-Bryan, S., Cassady, J. R., Tarbell, N. J., Blattner, S. R., Tantravahi, R., Leavitt, P., & Sallan, S. E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151101 · Cited by 416
Self-citationSallan, S. E., Hitchcock‐Bryan, S., Gelber, R. D., Cassady, J. R., Frei, E., & Nathan, D. (1983) · PubMed · Cited by 220
Self-citationL-Asparaginase: Clinical, Biochemical, Pharmacological, and Immunological Studies
CAPIZZI, R. L., BERTINO, J. R., SKEEL, R. T., CREASEY, W. A., ZANES, R., OLAYON, C., PETERSON, R. G., & HANDSCHUMACHER, R. E. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-6-893 · Cited by 180
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children
Tallal, L., Tan, C., Oettgen, H., Wollner, N., McCarthy, M., Helson, L., Burchenal, J., Karnofsky, D., & Murphy, M. L. (1970) · Cancer · doi:10.1002/1097-0142(197002)25:2<306::aid-cncr2820250206>3.0.co;2-h · Cited by 174
Biochemical and pharmacological studies with asparaginase in man.
Ohnuma, T., Holland, J. F., Freeman, A. I., & Sinks, L. F. (1970) · PubMed · Cited by 155
Killander, D., Dohlwitz, A., Engstedt, L., Franzén, S., Gahrton, G., GULLBRING, B., Holm, G., Holmgren, A., Höglund, S., KILLANDER, A., et al. (1976) · Cancer · Cited by 143
Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Nesbit, M., Chard, R. L., Evans, A., Karon, M., & Hammond, G. D. (1979) · PubMed · Cited by 88
Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Park, Y. K., Abuchowski, A., Davis, S., et al. (1981) · PubMed · Cited by 72
Cited by
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Use of ?-asparaginase in childhood ALL
Müller, H. (1998) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00015-8 · Cited by 455
Duval, M. (2002) · Blood · doi:10.1182/blood.v99.8.2734 · Cited by 408
Metadata
- Authors
- Asselin, B. L., Whitin, J. C., Coppola, D. J., Rupp, I. P., Sallan, S. E., & Cohen, H. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-09
- Volume
- 11
- Issue
- 9
- Pages
- 1780-1786
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1940732706
- Cited by
- 333
- References
- 12
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative pharmacokinetic studies of three asparaginase preparations. https://app.cochat.ai/papers/10.1200/jco.1993.11.9.1780
- The paper
- Asselin, B. L., Whitin, J. C., Coppola, D. J., Rupp, I. P., Sallan, S. E., & Cohen, H. J. (1993). Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.9.1780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.